Peter Horby

Has grant

Professor of Emerging Infectious Diseases

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Peter Horby is a faculty member at the University of Oxford, specializing in Emerging Infectious Diseases. His research areas include the clinical outcomes of infectious diseases, vaccine efficacy, and the management of high-consequence infectious diseases. Recent publications address notable topics such as mpox virus disease, COVID-19 outcomes, and the clinical management of infections like bubonic plague and Lassa fever.

Recent Grants

Grant: Close

Affordable and scalable remote monitoring platforms for disease characterisation and patient management in pandemics and for high-consequence infections

Open Date: 2022-04-01

Close Date: 2023-03-31

Grant: Close

New adaptive platform designs for clinical trials in an emerging disease epidemic

Open Date: 2022-03-27

Close Date: 2024-03-27

Grant: Close

RECOVERY International

Open Date: 2020-12-01

Close Date: 2023-05-31

Grant: Close

The African coaLition for Epidemic Research, Response and Training, Clinical Characterization Protocol (ALERRT CCP)

Open Date: 2020-08-13

Close Date: 2022-08-12

Grant: Close

LASCOPE extension

Open Date: 2020-06-15

Close Date: 2020-09-14

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Collaborators (18)

Stefan Schilling

Lecturer

University of Exeter

UNITED KINGDOM

Peter Horby

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (14)

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Europe needs a sustainably funded influenza research and response network.

Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)

Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.

Vaccine Effects on In-hospital COVID-19 Outcomes.

T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

'Involve those who are managing these outbreaks': stakeholders' perspectives on the barriers and facilitators to the implementation of clinical management guidelines for high-consequence infectious diseases in Uganda-a thematic network analysis.

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.

Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.

Group sequential designs for clinical trials when the maximum sample size is uncertain

Ebola virus disease in pregnancy: a systematic review and meta-analysis

Why preprints are good for patients

Time to reconsider the role of ribavirin in Lassa fever

Collaborators (18)

Stefan Schilling

Thomas Darton

france Mentré

Vishal Dey

Tom Fletcher

Silke Stertz

Shevin Jacob

Ron Fouchier

Effrossyni Gkrania-Klotsas

Cédric LAOUENAN

Leon Peto

David Allsup

Tansy Edwards

Nzelle Delphine Kayem

Stephen Kennedy

Elizabeth Bancroft

James Meiring

Ingeborg Welters

Make your next move.